Etan Hon Named Product Manager of Turbo Aftermarket Services for Nikkiso Cryogenic Services
TEMECULA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is pleased to announce that Etan Hon has been appointed Product Manager of Turbo Aftermarket Services (AMS) for the Nikkiso Cryogenic Services unit (NCS).
This addition to their management team supports the Group’s objectives to further grow their AMS for Turboexpanders. The Turbo All Brands line will also expand to support and service more brands, including ACD, Rotoflow, Atlas Copco, and Cryostar among others.
Etan received a degree in Aerospace engineering from the University of California, San Diego. He started his career by providing oilfield services to customers within the oil & gas industry in Texas working for Schlumberger and Baker Hughes. In 2017, he joined ACD LLC as a Field Service Manager. After the acquisition by Nikkiso in 2019, he transitioned into the role of Service Manager of Turbo AMS for NCS and helped move the ACD Turbo AMS division into a new facility in Irvine, CA. He helped re-develop the standards and processes with the international service centers for the Turbo AMS in Irvine. The new structure has created a successful operating business locally and will ensure proper support to the Turbo AMS team globally.
“The NCS team is excited to have Etan in this new Turbo AMS Product Management role,” according to Jim Estes, President of NCS. “His years of experience and focus on customer service has exceeded our expectations. I’m looking forward to his success continuing in this new role.”
Nikkiso Cryogenic Services provides service and support globally, including locations in Malaysia, Germany, India, Australia, Taiwan and China as well as six locations in North America.
ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly-controlled group of approximately 20 operating entities.
For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.
MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised23.4.2024 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Q1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), Cosentyx (+25% cc), Kesimpta (+66% cc), Kisqali (+54% cc), Pluvicto (+47% cc) and Leqvio (+139% cc)Core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net sales Operating income grew +39% (cc, +29% USD) and net income grew +37% (cc, +25% USD), mainly driven by higher net salesCore EPS grew +23% (cc, +17% USD) to USD 1.80Free cash flow1 USD 2.0 billion (-24% USD) declined due to a prior-year one-timer and timing of paymentsQ1 selected innovation milestones:Fabhalta (iptacopan) FDA filing accepted for IgAN and positive CHMP opinion for PNH Scemblix Phase III ASC4FIRST study met both primary endpoints in 1L Ph+ CML-CP patientsPluvicto Phase III PSMAfore updated OS results demonstrated HR<1.0 in pre-taxane mCRPCRemibrutinib Phase III 52-week data sh
Idorsia publishes an invitation to a bondholder meeting23.4.2024 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, including an extension of the maturity by six months. Allschwil, Switzerland – April 23, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has published an invitation to a bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds). At the meeting, the company is proposing a change to the current terms of the Bonds to avoid potential liquidity constraints in connection with the redemption of the Bonds. Bondholders can access the invitation to the bondholder meeting at the following link: www.idorsia.com/2024-bond André C. Muller, Chief Financial Officer, commented: “Based on many interactions with some significant bondholders, we have decided to adjust our initial proposal, by substantially reducing the conversion price
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia23.4.2024 07:00:00 CEST | Press release
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accelerate and build a portfolio of next-generation transformative treatments for immune diseasesIn addition to ITP, rilzabrutinib is being studied across a variety of immune-mediated diseases including asthma, chronic spontaneous urticaria, prurigo nodularis, IgG4-related disease and warm autoimmune hemolytic anemia Paris, April 23, 2024. Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response
eQ Plc’s interim report Q1 2024 – eQ’s profit fell23.4.2024 07:00:00 CEST | Press release
eQ Plc interim report 23 April 2024 at 8:00 AM January to March 2024 in brief During the financial period, the Group's net revenue totalled EUR 16.5 million (EUR 17.7 million from 1 Jan. to 31 Mar. 2023). The Group’s net fee and commission income was EUR 16.0 million (EUR 17.5 million). The Group’s operating profit fell by 12% to EUR 8.8 million (EUR 10.0 million).The Group’s profit was EUR 7.0 million (EUR 7.9 million). The consolidated earnings per share were EUR 0.17 (EUR 0.20).The net revenue of the Asset Management segment decreased by 11% to EUR 15.1 million (EUR 17.1 million) and the operating profit by 18% to EUR 8.9 million (EUR 10.7 million). The management fees of the Asset Management segment fell by 10% to EUR 14.0 million (EUR 15.6 million) and the performance fees fell by 17% to EUR 1.4 million (EUR 1.6 million). Assets under management increased by 3% to EUR 13.3 billion during the period under review (EUR 12.9 billion 31 Dec 2023). The net revenue of the Corporate Finan
Sequana Medical announces Annual General Meeting of Shareholders on 25 May 202323.4.2024 07:00:00 CEST | Press release
PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Publication of Annual Report 2023 Ghent, Belgium – 23 April 2024– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Annual and Extraordinary General Meetings of Shareholders on Thursday, 23 May 2024. The annual report for the financial year 2023 has been published on Sequana Medical's website and can be accessed here. The items on the agendas of the meetings include (among other) the proposed approval of a number of resolutions relating to the financial year ended 31 December 2023, the proposed approval of the revised remuneration policy, the proposed reappointment of the statutory auditor, the application of Article 7:151 of the Belgian Companies and Associations Code, the proposed contribution in kind of certain receivables pu